Anavex life sciences presents preliminary clinical efficacy data from the u.s. rett syndrome phase 2 anavex®2-73 study at the 6th annual european rett syndrome conference

Anavex life sciences corp. presented preliminary clinical efficacy data from the pk cohort (part a) of the u.s. phase 2 rett syndrome clinical trial anavex®2-73-rs-001. the data from the pk cohort (part a, n=6) is very encouraging because of the magnitude of change (large to very large effect sizes; cohen’s d: rsbq total 1.47; cohen’s d: glutamate 1.11), the efficacy signal on both caregiver- and clinician-based measures of severity and correlations with key biomarker related to disease pathogenesis (glutamate), the short duration of treatment with anavex®2-73 (blarcamesine), the relatively low dose, the older age of participants, and the clinical significance (rsbq-cgi-i correlations).
AVXL Ratings Summary
AVXL Quant Ranking